Respiratory Syncytial Virus Infection in Patients with Hematological Diseases: Single-Center Study and Review of the Literature

Khanna, Nina; Widmer, Andreas F.; Decker, Michael D.; Steffen, Ingrid; Halter, Jörg; Heim, Dominik; Weisser, Maja; Gratwohl, Aloïs; Flückiger, Ursula; Hirsch, Hans H.

doi:10.1086/525263

Cited by 226 publications

(311 citation statements)

References 41 publications

Supporting

Mentioning

283

Contrasting

Unclassified

Order By: Relevance

“…8 Reported side effects included hemolysis, leukopenia and hyperbilirubinemia. 9,14,16 In our study, no related side effects were observed, which was consistent with previous studies reporting on the use of ribavirin in the hepatitis C infection setting. 17 Recently, Shah et al 6 reviewed and summarized the use of ribavirin from 26 available studies involving adult HSCT patients infected with RSV.…”

Section: Intravenous Ribavirin In Pediatric Hematopoietic Transplantasupporting

confidence: 92%

“…3 The frequency of RSV infection in adults is about 2-17% among HSCT recipients. 6,9,10 This incidence is lower than that observed in the present study conducted in infants. Severity is highest in HSCT patients.…”

Section: Discussioncontrasting

confidence: 81%

“…Severity is highest in HSCT patients. Characteristics of patients were defined as severe immunodeficiency based on criteria adapted from Khanna et al 9 All the patients were under HSCT o6 months before diagnosis of RSV infection. Two patients fulfilled only this criterion, whereas four patients fulfilled two criteria (episodes 2, 5, 6 and 7) and three patients fulfilled Xthree criteria (episodes 4, 8 and 9) because of T-cell depletion, leukopenia, lymphopenia, hipogammaglobulinemia and/or pre-engraftment period.…”

Section: Discussionmentioning

confidence: 99%

“…Concerning RSV-related mortality, Khanna et al 9 reviewed the literature and reported mortalities of 38% in patients with RSV-LRTI treated with aerosolized ribavirin, 43% in patients treated with the combination of ribavirin and IVIG, and 64% in patients treated with i.v. ribavirin.…”

Section: Intravenous Ribavirin In Pediatric Hematopoietic Transplantamentioning

confidence: 99%

See 3 more Smart Citations

Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients

Molinos-Quintana

Soto

Gómez-Rosa

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

A Molinos-Quintana, C Pé rez-de Soto, M Gó mez-Rosa, JA Pé rez-Simó n and JM Pé rez-HurtadoRespiratory syncytial virus (RSV) is a potential cause of serious morbidity and even mortality among children undergoing hematopoietic SCT (HSCT). Contrary to the available information regarding the aerosolized formulation of ribavirin, there is a paucity of published studies using i.v. ribavirin in adults, and very few single reports on pediatric patients. Aerosolized drug administration has been limited by potential toxicity and special air-flow requirements. In this regard, i.v. ribavirin could prevent these disadvantages, but its efficacy and safety remain controversial in the pediatric HSCT setting. The present study describes the outcome of six pediatric patients undergoing HSCT with nine episodes of proven RSV. Four episodes corresponded to lower respiratory tract infection (LRTI) and five presented with upper respiratory tract infection (URTI). All LRTI patients showed favorable clinical responses, with 100% survival and no progression to LRTI in the remaining five URTI. No side effects were documented during ribavirin administration. We conclude that ribavirin was well tolerated intravenously, without associated side effects, and was effective in the treatment of RSV in this limited number of pediatric HSCT patients. The role and efficacy of i.v. ribavirin needs to be further clarified by prospective controlled trials in pediatric populations.

show abstract

Section: Intravenous Ribavirin In Pediatric Hematopoietic Transplantasupporting

confidence: 92%

Section: Discussioncontrasting

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Section: Intravenous Ribavirin In Pediatric Hematopoietic Transplantamentioning

confidence: 99%

See 2 more Smart Citations

Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients

Molinos-Quintana

Soto

Gómez-Rosa

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Es uno de los virus más frecuentes, con incidencia de 3,4-10% en TOS; 3,5-9% en TPH alogeneico y 0,4-1,5% en TPH autólogo 9 . La progresión a neumonía en estudios recientes es de 55%, con una mortalidad de 7% 9,14 .…”

Section: Epidemiologíaunclassified

Profilaxis de infección por virus respiratorios en niños y adultos sometidos a trasplante de órganos sólidos y precursores hematopoyéticos

Álvarez

Catalán

Alba³

et al. 2012

Rev. chil. infectol.

View full text Add to dashboard Cite

Respiratory Viruses After Hematopoietic Cell Transplantation

Seo

Boeckh

2015

Thomas’ Hematopoietic Cell Transplantation

View full text Add to dashboard Cite

Respiratory Syncytial Virus Infection in Patients with Hematological Diseases: Single-Center Study and Review of the Literature

Abstract: Lower RTI, >or=2 SID criteria, and preengraftment are risk factors for RSV-attributed mortality. Polymerase chain reaction may optimize diagnosis and monitoring. Oral ribavirin therapy seems safe, but trials are needed to demonstrate its efficacy.

Cited by 226 publications

References 41 publications

Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients

Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients

Profilaxis de infección por virus respiratorios en niños y adultos sometidos a trasplante de órganos sólidos y precursores hematopoyéticos

Respiratory Viruses After Hematopoietic Cell Transplantation

Contact Info

Product

Resources

About